Navigation Links
Pharmos Corporation Completes Initial Closing of Private Placement
Date:1/3/2008

ISELIN, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has completed an initial closing of a private placement of its 10% Convertible Debentures due November 2012. At the initial closing the Company issued $4,000,000 principal amount of the Debentures, at par, and received gross proceeds in the same amount.

The purchasers consisted of certain existing investors in the Company, namely Venrock Associates, New Enterprise Associates, Lloyd I. Miller, III and Robert Johnston.

The Debentures mature the earlier of November 1, 2012 or the sale of the Company. The Debentures, together with all accrued and unpaid interest thereon, may be repaid, without premium or penalty, commencing on November 1, 2011.

Starting on November 1, 2009 (or earlier sale of the Company), any outstanding Debenture may be converted at the option of the holder. The conversion price is fixed equal to $0.70 per share.

The Debentures bear interest at the rate of 10% per annum, payable semi-annually either in cash or common stock of the Company at the option of the Company.

Under the terms of the offering, the Company may raise gross proceeds up to an aggregate of $8,000,000 from the sale of Debentures in the placement (including the Debentures issued at the initial closing). A second closing is targeted for no later than 45 days from the date of the initial closing.

The proceeds will be used for working capital, in particular for the ongoing Phase 2b trial for dextofisopam.

The securities issued and issuable in the offering have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmos Corporation Announces Board and Management Changes
2. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Reports 2007 Third Quarter Results
5. Pharmos Issues Letter to Shareholders
6. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
9. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... , June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris ... a late-stage drug development company specialized in oncology and ... announced registered direct offering of US$12.1 million ... purchase warrants to certain institutional investors. Net proceeds from ...
... June 21, 2010 The Pharmaceutical practice,at MarketsandMarkets is pleased to announce a new report ... , ... , , ... , , ...
... in power capacity as a result of a new finding ... for one of the battery,s electrodes produced a significant increase ... it could deliver from a given weight of material, compared ... in small portable devices, and with further research might also ...
Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 2Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 4Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 2Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 3
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
(Date:7/9/2014)... southern Europe are less fit in terms of ... European peers. Moreover, southern adolescents are more obese ... fat than those from the centre-north of Europe. ... from an ambitious study conducted by scientists from ... in collaboration with 25 other European research groups. ...
(Date:7/9/2014)... yield big savings, if they are used in ... the Brigham and Women,s Hospital and coauthors analyzed ... savingshigh-cost patients; readmissions; triage; decompensation (when a patient,s ... a disease affects multiple organ systems. They suspect ... current costs associated with all six scenarios will ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
... CITY, MO Cells trying to keep pace with constantly ... between maintaining their genomic integrity and allowing enough genetic ... study, researchers at the Stowers Institute for Medical Research ... genomes become unstable, readily acquiring or losing whole chromosomes ...
... the genetic variance of human metabolism, researchers have identified ... with levels of circulating metabolites, i.e., small molecules that ... Many of the studied metabolites are biomarkers for cardiovascular ... provide valuable insight into the biological processes leading to ...
... the researchers to see an aspect of light that humans ... sensitive to polarized light, many reef dwelling animals are but ... studies of reef communities. Thanks to generous support provided ... team of researchers from the Ecology of Vision Laboratory in ...
Cached Biology News:That which does not kill yeast makes it stronger 2That which does not kill yeast makes it stronger 3Genetic regulation of metabolomic biomarkers - paths to cardiovascular diseases and type 2 diabetes 2Capturing an octopus-eye view of the Great Barrier Reef 2
... The mycobacteria in Complete Freund's adjuvant attract ... site which enhances the immuneresponse. For this ... for the initial injections; Incomplete Freund's adjuvant ... (preferably in saline) are typically mixed with ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
Biology Products: